ENHERTU® (fam-trastuzumab deruxtecan-nxki) | Official HCP Site
Discover ENHERTU, an FDA-approved treatment option. See Prescribing Information, including Boxed WARNINGS.
Total Visits
Avg. Visit Duration
Pages per Visit
Bounce Rate
Registration Date
| Month | Traffic |
|---|---|
| 2025-02 | 67.448 |
| 2025-03 | 74.498 |
| 2025-04 | 48.393 |
| 2025-05 | 58.714 |
| Source | Traffic Share |
|---|---|
| direct | 43.67% |
| search | 42.36% |
| referrals | 6.44% |
| social | 6.04% |
| paid referrals | 1.40% |
| 0.09% |
| Region | Percentage |
|---|---|
| United States | 96.54% |
| United Kingdom | 3.46% |
| Keyword | Traffic | Volume | CPC |
|---|---|---|---|
| enhertu | 1,861 | 18,610 | $4.46 |
| her2-positive | 22 | 220 | $0.00 |
| how often does triple negative breast cancer reappear? | 0 | 0 | $0.00 |
| plutonium treating cancer paients | 0 | 0 | $0.00 |
| is enhertu considered a high-emetic risk anticancer agent per nccn guidelines | 4 | 40 | $0.00 |